Using an @entity650 challenge to evaluate neuropsychological performance in XXXX .

@entity1 @entity650 @entity73 @entity1295 @entity281 @entity683 @entity5815
BACKGROUND: Individuals with acute @entity281 experience a range of symptoms including @entity1295 , muscle aches, and difficulties with concentration and memory that are usually self-limited. This cluster of symptoms is otherwise, similar to those that characterize @entity5815 ( @entity5815 ). The goal of the present study was to evaluate the cognitive and psychological functioning of @entity5815 @entity1 and normal controls (NCs) when they both were experiencing acute @entity683 -like symptoms. To induce @entity683 -like symptoms, we administered @entity650 ( @entity650 ), a cytokine that temporarily activates the acute phase immunological and endocrine responses. METHODS: Nineteen @entity1 who met the 1994 International @entity5815 Study Group Criteria and ten normal controls (NCs) completed routine clinical evaluations, neuropsychological tests of short-term memory, selective attention, and executive control, and self-ratings of somatic symptoms and psychological mood before, shortly following, and 1 day after @entity650 administration. RESULTS: @entity5815 @entity1 consistently reported more somatic symptoms, even when both groups perceived that they were ill. Both groups somatic symptoms increased during the @entity650 challenge, but the @entity5815 @entity1 symptoms increased more rapidly than controls. In general, the @entity5815 @entity1 performed similarly to NCs on the cognitive measures before, during, and after the @entity650 . In contrast to predictions, @entity650 provocation did not impair the cognitive performance of either @entity5815 @entity1 or NCs. CONCLUSIONS: The @entity650 provocation exacerbated the @entity1 self-reported symptoms but did not reveal notable @entity73 between @entity1 and controls during cytokine-induced acute @entity683 -like symptoms.
